Biohit Oyj is renewing its organization as part of its 2024-2028 growth strategy. The organizational change aims to strengthen the strategic and operational performance of R&D. The changes enter into force on August 12, 2024. Biohit?s R&D Director and Member of the Management Team, Panu Hendolin, Ph.D. (Molecular Medicine), has been appointed the company?s Chief Technology Officer.

In addition to strategic management of R&D, Hendolin will in the future be responsible for instruments and monoclonal antibodies. Hendolin will continue as a Member of Biohit?s Management Team. Marika Karjalainen, M.Sc.

(Biochemistry), has been appointed as the new R&D Director. Karjalainen will be responsible for the operational management of R&D. Karjalainen transfers to Biohit from Aiforia Technologies Oyj, where she has worked, for example, as Senior Manager of Regulatory Affairs. Karjalainen is an important Biohit returnee, she worked as a project manager in the company in 2018-2021.

Karjalainen has also worked in R&D-related positions at VTT Technical Research Centre of Finland and Orion Diagnostica.